GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Yu Sunakawa (Japan) provides the highlights on cancer of the liver, small intestine and pancreas tract.
GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Yu Sunakawa (Japan) provides the highlights on cancer of the liver, small intestine and pancreas tract.
Dr Yu Sunakawa is a medical oncologist at St. Marianna University, Japan and previously worked as an instructor at Showa University Northern Yokohama Hospital in Yokohama, Japan. He also completed postdoctoral research fellowship training at University of Southern California/Norris Comprehensive Cancer Center in United States. In 2011, Dr Sunakawa received the board certification of the Japanese Society of Medical Oncology. Dr Sunakawa’s research interests are the identification and determination of molecular markers in cancerous tissues or blood that could predict cancer risk and clinical outcome in gastrointestinal cancer. He is also focusing on research regarding tumour immunity and received a Merit Award from the American Society of Clinical Oncology in 2014, for the research of genetic variations in immune checkpoint-related genes.
Bayer, Bristol-Myers, Biopharma, Chugai Pharm, Daiichi-Sankyo, Gurdant, Lilly, Ono Pharm, Sanofi, Sysmex, Takeda and Tahio Pharm.
From sample collection through to diagnostic modalities
Medical experts discuss how to approach sequencing in clinical practice
Medical experts share their insights on testing and treatment
Medical experts discuss safety and efficacy of IO and IO combinations, clinical trial data, and best practice
Expert opinion on the clinical application of artificial intelligence (AI)
Medical experts share insights and review key clinical trials